Format

Send to

Choose Destination
See comment in PubMed Commons below
Dis Mon. 2007 Apr;53(4):214-22.

Current pharmacotherapeutic treatment options in Parkinson's disease.

Author information

1
Northwestern University, Feinberg School of Medicine, Movement Disorders Program, Evanston Northwestern Healthcare, Evanston and Glenbrook Hospitals, Evanston and Glenview, Illinois, USA.

Abstract

Treatment options for Parkinson's disease have greatly expanded in recent years. Pharmacological treatments, such as levodopa, dopamine receptor agonists, anticholinergic medications, monoamine oxidase B inhibitors, and the catechol-O-methyl transferase inhibitors, remain the mainstay of therapeutic intervention and are reviewed. Additionally, the traditional and new roles for amantadine are explained. Despite the great efficacy of levodopa, "levodopa-sparing strategies" in early Parkinson's disease are emphasized in order to delay the development of difficult-to-manage motor fluctuations and dyskinesias.

PMID:
17586328
DOI:
10.1016/j.disamonth.2007.05.002
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Support Center